XML 47 R38.htm IDEA: XBRL DOCUMENT
v3.25.3

Fair Value Measurements (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Fair Value Disclosures [Abstract] |
Schedule of Assets and Liabilities measured at Fair Value | Assets and liabilities measured at fair value are summarized below (in thousands):
Description |  | September 30, 2025 |  |  | Quoted Prices in Active Markets for Identical Assets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Assets: |  |  |  |  |  |  |  |  |  |  |  |
Cash equivalents (Note C) |  | $ | 413 |  |  | $ | 413 |  |  | $ | — |  |  | $ | — |
Related party note receivable |  |  | 5,725 |  |  |  | — |  |  |  | 5,725 |  |  |  | — |
Investment in MiNK Therapeutics, Inc. |  |  | 30,482 |  |  |  | 30,482 |  |  |  | — |  |  |  | — |
Long-term investments |  |  | 849 |  |  |  | 849 |  |  |  | — |  |  |  | — |
Total |  | $ | 37,469 |  |  | $ | 31,744 |  |  | $ | 5,725 |  |  | $ | — |
Description |  | December 31, 2024 |  |  | Quoted Prices in Active Markets for Identical Assets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Assets: |  |  |  |  |  |  |  |  |  |  |  |
Cash equivalents (Note C) |  | $ | 6,954 |  |  | $ | 6,954 |  |  | $ | — |  |  | $ | — |
Long-term investments |  |  | 1,006 |  |  |  | 1,006 |  |  |  | — |  |  |  | — |
Total |  | $ | 7,960 |  |  | $ | 7,960 |  |  | $ | — |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Purchaser Upsize Option (Note F) |  | $ | 69 |  |  |  |  |  |  |  |  | $ | 69 |
Contingent purchase price consideration |  |  | 318 |  |  |  | — |  |  |  | — |  |  |  | 318 |
Total |  | $ | 387 |  |  | $ | — |  |  | $ | — |  |  | $ | 387 |
We measure the Related party note receivable at fair value. The fair value of the Note Receivable at September 30, 2025 was approximately $5.7 million, using a scenario based present value methodology that was derived by evaluating the nature and terms of the Note Receivable and considering the prevailing economic and market conditions at the balance sheet date, some of which are considered Level 2 inputs under the fair value measurements standard. As of September 30, 2025 the Note Receivable had a principal balance of $5.0 million. Our long-term equity investment in MiNK is measured at fair value and is calculated using readily determinable pricing available on a securities exchange and is classified as a Level 1 asset. Other l

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration